91
67
Growth Score
4 pts
Heat Score
-20 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4129632
Bio4t2 develops CAR-T cell therapies for solid tumors using platforms such as PrismCore, Bio-Engine, Bi-CAR-T and Bio-Strike.
About the Company
Bio4t2 develops chimeric antigen receptor T cell therapies to treat patients with solid tumors. The company uses its PrismCore platform to design CAR-T cells that recognize self-antigens when overexpressed on tumor cells, while limiting activity on normal tissues. Its Bio-Engine technology is designed to enhance CAR-T engraftment and persistence
without preparative chemotherapy, enabling repeat dosing. Bio-Strike adds an inducible safety switch to allow selective elimination of administered T cells if needed. Bio4t2 advances investigational candidates such as B4t2-001 and Bi-CAR-T through early-stage clinical trials. It operates as a privately held biopharmaceutical portfolio company of Bridgewest Group.
